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Introduction {#sec1}
============

Proinflammatory cytokines such as IL-1, IL-6, IL-17, IL-23, GM-CSF, and TNF-α are important in the development and maintenance of chronic inflammatory disorders such as autoimmune disease. Neutralization of these cytokines or blockade of their receptors is effective in hampering the progression of tissue inflammation and inducing long-term remission in autoimmune disorders ([@bib10]). Recent genome-wide association studies of immune-mediated diseases have revealed common inflammatory pathways, involving the genes encoding these cytokines and receptors, in various autoimmune diseases ([@bib39]). It remains to be determined, however, how key inflammatory cytokines control non-lymphoid as well as lymphoid target cells in autoimmune tissue inflammation, how environmental factors, as well as genetic factors, contribute to the inflammation, and how the cytokine-dependent inflammatory pathways can be targeted to treat or prevent autoimmune diseases.

IL-17-producing T helper (Th17) cells play critical roles for host defense against infectious pathogens but can also mediate various autoimmune or inflammatory reactions. They express the lineage defining transcription factor Rorγt and require IL-6 and TGF-β for their differentiation and IL-1 and IL-23 for their terminal effector functions ([@bib28], [@bib35], [@bib48]). In rheumatoid arthritis (RA), for example, it has been shown that various inflammatory cytokines including TNF-α, IL-1, and IL-6 are involved in joint inflammation and that T cells interact with tissue-resident macrophage-like or fibroblast-like synoviocytes (FLSs) in destroying cartilage and bone in the joint ([@bib4]). It still remains unclear, however, how arthritogenic Th17 cells mediate chronic tissue inflammation in the joint via local cytokine and cellular networks.

GM-CSF is a key proinflammatory cytokine for the activation of dendritic cells (DCs) and macrophages; for example, DCs respond to GM-CSF to secrete IL-6 and IL-23, which sustain pathogenic Th17 cells *in vivo* ([@bib44]). Moreover, IL-1 and IL-23 signaling drives Rorγt-expressing Th17 cells to secrete GM-CSF, perpetuating autoimmune inflammation, for example, in mouse experimental autoimmune encephalomyelitis (EAE) ([@bib11], [@bib16]). The antigen-presentation capacity of monocytes and synovial inflammatory macrophages can also be enhanced by stimulation with GM-CSF through upregulation of MHC class II expression ([@bib1]). In addition, GM-CSF signaling evokes an inflammatory signature in CCR2^+^Ly6C^hi^ monocytes and drives them to induce tissue damage ([@bib14]). GM-CSF thus appears to possess pleiotropic effects on monocytes and/or DCs and Th17 cells, augmenting the activation of innate and adaptive immune cells and amplifying tissue inflammation.

The SKG strain of mice, carrying a point mutation in the gene encoding the T cell receptor (TCR)-proximal signaling molecule ZAP-70, develops CD4^+^ T cell-mediated autoimmune arthritis, which clinically and immunologically resembles RA in humans ([@bib21], [@bib42]). The mice spontaneously develop the disease in a microbially conventional environment but not under a specific-pathogen-free (SPF) condition. Yet the disease can be induced in SPF SKG mice by stimulation of innate immunity via Toll-like receptors (TLRs), the Dectin pathway, or complement activation pathways ([@bib20], [@bib51]). We previously demonstrated, by using SKG mice, how self-reactive T cells are generated in the process of thymic-positive and -negative selection ([@bib42]), become activated in the periphery by recognizing self-antigens, differentiate into arthritogenic Th17 cells upon stimulation of innate immunity ([@bib22]), migrate into the joints ([@bib23]), and aggress self-antigens expressed by synoviocytes ([@bib27]). In addition, dysfunction of Foxp3^+^ regulatory T cells due to the ZAP-70 mutation facilitates autoimmune T cells to expand, become activated, and exert their effector functions, causing autoimmune diseases in a wide spectrum of organs or tissues ([@bib46]). These features make this spontaneous model of autoimmune arthritis suitable for elucidating how Th17 cells mediate autoimmune diseases, especially RA, via interacting with other lymphoid and non-lymphoid cells at the inflammation site and controlling their production of inflammatory cytokines.

In this report, we showed via the SKG model of autoimmune arthritis that arthritogenic Th17 cells orchestrated the progression of chronic joint inflammation by stimulating radio-resistant stromal cells including FLSs to secrete GM-CSF and subsequently by expanding GM-CSF-producing innate lymphoid cells (ILCs). Notably, GM-CSF secretion from ILCs was regulated by IL-2, the alarmin IL-33, and endogenous TLR-9 ligands released from damaged tissue-resident cells, in inflamed joints. The results demonstrate how antigen-specific self-reactive T cells stimulate the local cellular and cytokine networks that drive chronic tissue inflammation.

Results {#sec2}
=======

GM-CSF as a Crucial Inflammatory Mediator of Autoimmune Arthritis {#sec2.1}
-----------------------------------------------------------------

A single injection of 20 mg mannan, an activator of the lectin pathway for complement activation, is able to synchronously evoke T cell-mediated autoimmune arthritis within 2--3 weeks in SPF SKG mice with an increase in Th17 cells in lymph nodes and joints ([@bib20]). In the draining lymph nodes and inflamed joints of mannan-treated SKG mice, approximately 2% and 7%, respectively, of CD4^+^ T cells co-expressed IL-17 and GM-CSF, but not IFN-γ ([Figures 1](#fig1){ref-type="fig"}A and 1B). In addition, GM-CSF (encoded by *Csf2*)-deficient (*Csf2*^−/−^) SKG mice were highly resistant to the induction of autoimmune arthritis by mannan as were *Il17a*^−/−^ SKG mice, indicating a crucial role of GM-CSF for arthritis development in SKG mice ([Figure 1](#fig1){ref-type="fig"}C; [@bib22]).Figure 1GM-CSF-Producing T Helper Cells Are Dispensable for GM-CSF-Dependent Autoimmune Arthritis Development(A) Intracellular IL-17, IFN-γ, and GM-CSF staining of CD4^+^ T cells from popliteal LNs or inflamed joints.(B) Proportion of cytokine-producing cells in CD4^+^ T cells from individual mice as shown in (A). Vertical bars mean SD (n = 3).(C) Arthritis scores assessed in individual SKG, *Csf2*^−/−^ SKG, or *Il17a*^−/−^ SKG mice (n = 20 each) 3 months after single i.p. injection of 20 mg mannan.(D) Intracellular IL-17, IFN-γ, and GM-CSF staining of CD4^+^ T cells from inflamed joints of *Il17a*^*Cre*^ R26R^eYFP^ SKG mice.(E) Arthritis development after adoptive transfer of CD4^+^ T cells from WT or *Csf2*^−/−^ SKG mice into *Rag2*^−/−^ mice (n = 17 each, SEM). The severity of arthritis was monitored every week after transfer of 1 × 10^6^ CD4^+^ T cells.(F) Intracellular IL-17 and GM-CSF staining of CD4^+^ T cells from spleens and inflamed joints of *Rag2*^−/−^ mice with CD4^+^ T cells transfer as shown in (E).^∗^p \< 0.05, ^∗∗^p \< 0.01. Data are representative of three independent experiments (A, B, D, and F) or pooled from three experiments (C and E).

To determine the origin of such GM-CSF-producing cells in arthritic SKG mice, we generated IL-17-fate reporter SKG mice by crossing SKG mice with *Il17a*^*Cre*^ and R26R^eYFP^ fate reporter strains ([@bib24]). Following mannan treatment, more than 30% of CD4^+^ T cells in inflamed joints were eYFP^+^, indicating that they were producing IL-17 or had once produced the cytokine (exTh17 cells) ([Figure 1](#fig1){ref-type="fig"}D). In addition, one-third of eYFP^+^ cells were producing GM-CSF, indicating that IL-17-producing CD4^+^ T cells produced GM-CSF in inflamed joints. Also, only ∼5% of eYFP^+^ cells were producing IFN-γ, suggesting that differentiation toward Th1-like cells was not the main cell fate of Th17 or exTh17 cells in this model, in contrast with EAE, in which the vast majority of exTh17 cells were producing IFN-γ ([@bib24]).

Next, we adoptively transferred CD4^+^ T cells from *Csf2*^−/−^ or wild-type (WT) SKG mice into *Rag2*^−/−^ mice to determine the pathogenicity of GM-CSF-producing CD4^+^ T cells ([Figure 1](#fig1){ref-type="fig"}E). *Csf2*^−/−^ SKG CD4^+^ T cells were able to induce autoimmune arthritis in all the recipient mice, although arthritis was significantly less severe than that induced by WT SKG CD4^+^ T cell transfer. Analysis of IL-17 and GM-CSF production by CD4^+^ T cells in the spleen and inflamed joints revealed that IL-17-producing CD4^+^ T cells, which were crucial for initiating SKG autoimmune arthritis ([@bib22]), had similarly differentiated from *Csf2*^−/−^ or WT SKG CD4^+^ T cells ([Figure 1](#fig1){ref-type="fig"}F).

These results demonstrated that both T cell-derived and non-T cell-derived GM-CSF contributed to joint inflammation in SKG mice and that GM-CSF from Th cells was not mandatory for this induction of autoimmune arthritis.

GM-CSF Secreted from Non-T Cells Is Crucial for Initiating Autoimmune Arthritis {#sec2.2}
-------------------------------------------------------------------------------

To further assess the possible contribution of GM-CSF from non-CD4 T cells to arthritis development, we transferred *Csf2*^−/−^ or WT SKG CD4^+^ T cells into *Rag2*^−/−^ or *Csf2*^−/−^*Rag2*^−/−^ mice ([Figure 2](#fig2){ref-type="fig"}A). Transfer of *Csf2*^−/−^ SKG CD4^+^ T cells induced histologically evident arthritis in *Rag2*^−/−^ mice although the arthritis was macroscopically less severe than WT SKG CD4^+^ T cell transfer ([Figures 2](#fig2){ref-type="fig"}B and 2C). In contrast, not only *Csf2*^−/−^ SKG CD4^+^ T cells but also WT SKG CD4^+^ T cells completely failed to induce arthritis macroscopically and histologically in *Csf2*^−/−^*Rag2*^−/−^ mice. Intracellular cytokine staining of transferred *Csf2*^−/−^ or WT SKG CD4^+^ T cells revealed that both populations were activated and had differentiated into IL-17-producing CD4^+^ T cells regardless of whether the hosts produced GM-CSF or not ([Figures 2](#fig2){ref-type="fig"}D and 2E). Thus, the failure in arthritis development following transfer of CD4^+^ T cells into *Csf2*^−/−^ hosts could be attributed not to impaired Th17 cell differentiation but to impaired GM-CSF production by certain host non-T cells stimulated by Th17 cells.Figure 2GM-CSF from Non-T Cells Is Crucial for the Initiation of Autoimmune Arthritis(A) Experimental design of adoptive transfer of CD4^+^ T cells from WT or *Csf2*^−/−^ SKG mice into *Rag2*^−/−^ or *Csf2*^−/−^*Rag2*^−/−^ mice. Arthritis scores of four groups (a--d) of mice were assessed 3 months after transfer of 1 × 10^6^ CD4^+^ T cells.(B) Arthritis scores of the four groups mice (n = 15 or 16 each) shown in (A). Horizontal bars indicate the means.(C) Representative joint histology of the groups shown in (A). Scale bars indicate 200 μm.(D) Flow cytometry of splenic CD4^+^ T cells stained for intracellular IL-17 and GM-CSF or IFN-γ.(E) Proportion of IL-17-producing CD4^+^ T cells from individual mice as shown in (D). Vertical bars mean SD (n = 3).^∗∗^p \< 0.01. Data are representative of three independent experiments (C--E) or pooled from three independent experiments (B).

FLSs Secrete GM-CSF in Response to IL-17 {#sec2.3}
----------------------------------------

We next attempted to determine the non-T cell source of GM-CSF in inflamed joints in SKG mice. FLSs are known to be key effector cells capable of secreting large amounts of pro-inflammatory mediators (e.g., tissue-degrading enzymes and cytokines such as TNF-α), which destroy the cartilage and bone in SKG arthritis as in human RA ([@bib4], [@bib21]). Gene expression analysis of FLSs that were freshly isolated from SKG arthritic joints and stimulated *in vitro* with recombinant IL-17 revealed quick upregulation within 1--3 hr of the expression of *Csf2*, *Ccl20*, *Cxcl1*, *Cxcl5*, *Il6*, *Nfkbiz*, *Lif*, and *Zc3h12a* ([Figure 3](#fig3){ref-type="fig"}A). Yet activated FLSs themselves neither expressed GM-CSF receptor-alpha nor responded to recombinant GM-CSF ([Figure S1](#mmc1){ref-type="supplementary-material"}A and data not shown). The cells predominantly expressing GM-CSF receptor-alpha in inflamed joints were CD11b^+^Ly-6C^+^Ly-6G^−^ inflammatory monocytes, as reported previously with EAE ([@bib14]), indicating that this population could be a main target of GM-CSF in the joint ([Figure S1](#mmc1){ref-type="supplementary-material"}B). In addition, cell transfer of WT, but not *Il17a*^−/−^, SKG CD4^+^ T cells into *Rag2*^−/−^ mice significantly induced *Csf2*, *Ccl20*, and *Il6* transcription in CD45^−^podoplanin^+^ synoviocytes that were purified from the joints 4 weeks after cell transfer ([Figure 3](#fig3){ref-type="fig"}B). Thus, one of the cellular targets of arthritogenic Th17 cells is FLSs, which secrete GM-CSF upon IL-17 stimulation.Figure 3Induction of GM-CSF in FLSs Stimulated with IL-17(A) Quantitative RT-PCR analysis for the expression of designated genes in IL-17-stimulated FLSs. FLSs (2.5 × 10^4^) were stimulated with 50 ng/mL rmIL-17 and harvested at the indicated time points. mRNA expression is presented relative to the expression of *Hprt1*.(B) Quantitative RT-PCR analysis for the expression of designated genes in synoviocytes from *Rag2*^−/−^ mice with CD4^+^ T cell transfer. CD45^−^Podoplanin^+^ synoviocytes (3 × 10^4^) were sorted from inflamed joints of *Rag2*^−/−^ mice 4 weeks after transfer of 1 × 10^6^ SKG or *Il17a*^−/−^ SKG CD4^+^ T cells. Vertical bars mean SD (n = 3).Data are representative of two independent experiments.

GM-CSF-Producing Synovial-Resident ILCs Expand in Arthritic Joints and Augment Autoimmune Arthritis {#sec2.4}
---------------------------------------------------------------------------------------------------

Next, in order to search for a potential hematopoietic source of GM-CSF other than T cells in joint inflammation, we prepared single-cell suspensions from enzyme-digested inflamed joints in *Rag2*^−/−^ mice that had received *Csf2*^−/−^ or WT SKG CD4^+^ T cells. By intracellular GM-CSF staining, CD4^+^ and non-CD4^+^ T cell populations in CD45^+^ hematopoietic cells contained similar percentages of GM-CSF-producing cells in *Rag2*^−/−^ mice transferred with WT SKG CD4^+^ T cells, whereas non-CD4 cells were the only source of GM-CSF in those transferred with *Csf2*^−/−^ SKG CD4^+^ T cells ([Figure 4](#fig4){ref-type="fig"}A). To characterize the non-CD4 source of GM-CSF, various CD45^+^ cell populations were purified from SKG inflamed joints by the use of cell lineage markers and assessed for their cytokine expression by quantitative RT-PCR ([Figure 4](#fig4){ref-type="fig"}B). The vast majority of joint-infiltrating cells were CD11b^+^Ly-6G^−^ inflammatory monocytes or macrophages and CD11b^+^Ly-6G^+^ neutrophils, a common feature of Th17 cell-mediated inflammation ([@bib29]). However, these populations of neutrophils and inflammatory monocytes did not express *Csf2* while they specifically expressed *Il1b*. In contrast, lymphoid populations including CD4^+^ T cells and lineage marker-negative ILCs expressed *Csf2* but not *Il1b*. 2% to 4% of CD45^+^ lymphocytes in arthritic joints were lineage-negative CD45^+^ ILCs, which were equivalent in ratio between *Rag2*^−/−^ mice transferred with *Csf2*^−/−^ or WT SKG CD4^+^ T cells ([Figures 4](#fig4){ref-type="fig"}C, 4D, and [S2](#mmc1){ref-type="supplementary-material"}A for gating strategy). We also found a fraction of synovial-resident ILCs in healthy joints of SKG mice (which are on the BALB/c background) and other mouse strains ([Figures 4](#fig4){ref-type="fig"}E, [S3](#mmc1){ref-type="supplementary-material"}A, and [S4](#mmc1){ref-type="supplementary-material"}). Expansion of these synovial ILCs expressing Ki-67 was detectable only in inflamed joints, but not in the draining LNs or bone marrow (BM), suggesting that synovial ILCs preferentially expanded in inflamed joints, but might scarcely migrate to the adjacent lymphoid organs ([Figures 4](#fig4){ref-type="fig"}E, 4F, and [S3](#mmc1){ref-type="supplementary-material"}B).Figure 4GM-CSF-Producing ILCs in Inflamed Joints(A) Flow cytometry analysis of GM-CSF expression by CD4^+^ T cells and CD4^−^ cells among CD45^+^ joint infiltrating cells in *Rag2*^−/−^ mice transferred with CD4^+^ T cells from WT or *Csf2*^−/−^ SKG mice.(B) Quantitative RT-PCR analysis of *Csf2*, *Il1b*, and *Tnf* in CD11b^+^Ly-6G^−^ (CD11b^+^), CD11b^+^Ly-6G^+^ (Ly-6G^+^), CD4^+^ T cells, and ILCs sorted from arthritic joints of mannan-treated SKG mice (n = 3). mRNA expression is presented relative to the expression of *Hprt1*.(C) Flow cytometry of joint infiltrating cells in *Rag2*^−/−^ mice transferred with CD4^+^ T cells from WT or *Csf2*^−/−^ SKG mice. Cells were stained for CD45.2 and lineage markers (a cocktail of CD3, CD4, CD8, CD11b, CD11c, CD19, and DX-5).(D) Proportion of ILCs in *Rag2*^−/−^ mice transferred with CD4^+^ T cells as shown in (C). Each symbol represents an individual mouse. Horizontal bars indicate the means.(E) Total cell number of ILCs from healthy or inflamed joints of SKG mice (n = 3).(F) Flow cytometry of synovial ILCs (CD45.2^+^ lineage markers-negative Thy1.2^+^ cells as shown in C) for Ki-67 expression.(G) Flow cytometry of synovial ILCs (CD45.2^+^ lineage markers-negative Thy1.2^+^ cells as shown in C) for cell surface expression of IL-7Ra, CD25, CCR6, c-kit, IL-33Ra, CD44, and MHC2.(H) Flow cytometry of synovial ILCs (as shown in C) for intranuclear expression of the transcription factor T-bet, Gata-3, Rorγt, and Foxp3.(I) Proportion of the transcription factor-expressing synovial ILCs (n = 3) as shown in (H).(J) Flow cytometry of synovial ILCs (as shown in C) for the expression of GM-CSF, Gata-3, and IL-13.(K) Total cell numbers of ILCs from healthy or inflamed joints of C57/BL6 (B6) mice with collagen antibody-induced arthritis (n = 3). Data are representative of two independent experiments.(L) Flow cytometry of synovial ILCs for the expression of GM-CSF and FP635 in arthritic *Il17a*^*Cre*^ R26R^FP635^ SKG mice.(M) Quantitative RT-PCR analysis of *Csf2* and *Bhlhe40* in splenic naive CD25^−^CD44^lo^CD4^+^ T cells (naive CD4^+^ T) and synovial ILCs (n = 3) as shown in (C).(N) The effects of ILC depletion on arthritis development. CD4^+^ T cells (1 × 10^6^) from Thy1.1^+^ SKG mice were adoptively transferred into Thy1.2^+^*Rag2*^−/−^ mice, which were i.v. injected with 500 μg anti-Thy1.2 mAb or control Rat IgG every week (n = 19 each). The severity of arthritis was monitored every week.^∗^p \< 0.05, ^∗∗^p \< 0.01. Data are representative of three independent experiments in (A)--(C), (E)--(J), (L), and (M) and pooled from more than two experiments in (D), (F), and (N). Vertical bars mean SD in (B), (E), (I), (K), (M), and (N).

By flow cytometry, most of the joint-infiltrating ILCs expressed IL-7Ra, CD25, IL-33Ra, and CD44, while nearly a half of them expressed c-kit and/or MHC class II, and ∼10% of them expressed CCR6 ([Figure 4](#fig4){ref-type="fig"}G). Further analysis of transcription factors defining ILC subsets revealed that approximately 60% and 6% of the ILCs expressed Gata-3 or Rorγt, respectively, indicating predominant expansion of ILC2s in arthritic joints, as shown in intestinal infection ([Figures 4](#fig4){ref-type="fig"}H and 4I; [@bib25]). Indeed, GM-CSF-producing ILCs in healthy and inflamed joints expressed Gata-3 and/or IL-13, which are the signature transcription factor and cytokine, respectively, of ILC2s ([Figures 4](#fig4){ref-type="fig"}J and [S3](#mmc1){ref-type="supplementary-material"}A). ILCs with a similar phenotype were also present in normal joints and expanded in collagen antibody-induced arthritis in C57/BL6 mice, indicating that the presence and expansion of GM-CSF-producing synovial ILCs was not dependent on the mouse genetic background or the mode of arthritis induction by autoimmune Th17 cells or autoantibody ([Figures 4](#fig4){ref-type="fig"}K and [S4](#mmc1){ref-type="supplementary-material"}). In addition, inflamed joints contained Rorγt-expressing ILC3s ([Figure 4](#fig4){ref-type="fig"}H). As ILC3s were reportedly able to produce GM-CSF in the intestine to maintain gut homeostasis ([@bib37]), we attempted with IL-17-fate reporter SKG mice to determine whether joint ILC3s, whose signature cytokine is IL-17, also produced GM-CSF. In correlation with the small percentage (∼6%) of Rorγt-expressing ILC3s shown in [Figure 4](#fig4){ref-type="fig"}H, joint ILCs contained a small fraction (∼4%) of IL-17-fate reporter-positive cells producing GM-CSF, suggesting that a part of GM-CSF-producing ILCs were derived from ILC3s in this model ([Figure 4](#fig4){ref-type="fig"}L). Synovial ILCs also highly expressed the transcription factor encoded by *Bhlhe40*, which reportedly controlled GM-CSF production by pathogenic Th cells ([Figure 4](#fig4){ref-type="fig"}M; [@bib32], [@bib34]).

To further determine the contribution of these ILCs to arthritis development, we attempted to selectively deplete ILCs by anti-Thy1.2 mAb in Thy1.2^+^ *Rag2*^−/−^ mice that had been transferred with CD4^+^ T cells from Thy1.1^+^ congenic SKG mice ([Figure 4](#fig4){ref-type="fig"}N). Multiple injections of 500 μg anti-Thy1.2 mAb every week indeed reduced the severity of autoimmune arthritis significantly.

Taken together, synovial ILCs selectively expanded in arthritic joints, secreting GM-CSF and contributing to the development of autoimmune arthritis.

GM-CSF from Both Radio-Resistant Stromal Cells Including FLSs and ILCs Is Essential for Autoimmune Arthritis Development {#sec2.5}
------------------------------------------------------------------------------------------------------------------------

To assess the contribution of GM-CSF from either stromal cells or ILCs to autoimmune arthritis, we x-irradiated (6Gy) *Rag2*^−/−^ or *Csf2*^−/−^*Rag2*^−/−^ mice, reconstituted the mice with *Rag2*^−/−^ or *Csf2*^−/−^*Rag2*^−/−^ BM cells, transferred to them *Csf2*^−/−^ SKG CD4^+^ T cells 6 weeks after BM reconstitution, and assessed arthritis score 12 weeks after CD4^+^ T cell transfer ([Figure 5](#fig5){ref-type="fig"}A). *Rag2*^−/−^ BM-transferred x-irradiated *Csf2*^−/−^ *Rag2*^−/−^ mice and *Csf2*^−/−^*Rag2*^−/−^ BM-transferred x-irradiated *Rag2*^−/−^ mice, in which GM-CSF production was restricted to ILCs or radio-resistant stromal cells including FLSs, respectively, developed significantly less severe arthritis than *Rag2*^−/−^ BM-transferred x-irradiated *Rag2*^−/−^ mice, in which both ILCs and radio-resistant stromal cells produced GM-CSF ([Figure 5](#fig5){ref-type="fig"}B). The percentage of total synovial ILCs expanding in inflamed joints was comparable between *Rag2*^−/−^ BM transfer and *Csf2*^−/−^*Rag2*^−/−^ BM transfer, although the total number of synovial ILCs was smaller in the latter chimeras presumably because of less severe synovial inflammation ([Figure 5](#fig5){ref-type="fig"}C, data not shown). Also, the latter still possessed a small number of recipient-derived GM-CSF-producing ILCs ([Figure 5](#fig5){ref-type="fig"}D), indicating that reduction, if not complete abrogation, of GM-CSF production in ILCs was able to attenuate arthritis severity. In addition, by *Csf2*^−/−^ BM transfer, the proportion of ILCs co-expressing GM-CSF and IL-13 decreased, with similar proportions of total IL-13^+^ ILCs, suggesting that joint inflammation had expanded *Csf2*^−/−^ ILCs, which appeared to be hardly pathogenic ([Figures 5](#fig5){ref-type="fig"}D and 5E).Figure 5GM-CSF from ILCs and Radio-Resistant Stromal Cells Is Crucial for Autoimmune Arthritis(A) Preparation of experimental groups for assessing arthritogenic effects of GM-CSF from ILCs or radio-resistant stromal cells. *Rag2*^−/−^ or *Csf2*^−/−^*Rag2*^−/−^ mice were x-irradiated (X-*Rag2*^−/−^ mice) and transferred with BM cells from *Csf2*^−/−^ or WT *Rag2*^−/−^ mice. The resulting four groups of BM chimeras were transferred with CD4^+^ T cells from *Csf2*^−/−^ SKG mice 6 weeks after BM reconstitution and assessed for arthritis development 12 weeks later.(B) Arthritis scores of four groups of mice shown in (A).(C) Proportion of total synovial ILCs from x-irradiated *Rag2*−/− mice reconstituted with *Csf2*^−/−^ or WT *Rag2*^−/−^ BM cells.(D) Flow cytometry of synovial ILCs for the expression of GM-CSF and IL-13 in arthritic joints of BM chimeras shown in (C).(E) Proportion of GM-CSF^+^IL-13^−^, GM-CSF^+^IL-13^+^, and GM-CSF^−^IL-13^+^ synovial ILCs (n = 6 each) as shown in (D).(F and G) The effects of ILC depletion on arthritis development. Thy1.1^+^*Rag2*^−/−^ mice were x-irradiated and transferred with BM cells from Thy1.1^+^*Rag2*^−/−^ and Thy1.2^+^*Csf2*^−/−^ SKG mice. The resulting BM chimeras were i.p. injected with 20 mg mannan 6 weeks later, followed by i.v. injection with 500 μg anti-Thy1.1 mAb or control Rat IgG every week. Flow cytometry of synovial ILCs for GM-CSF and IL-13 expression (F). Arthritis scores in each group of mice monitored every week (G). Vertical bars mean SD (n = 8 each).^∗^p \< 0.05, ^∗∗^p \< 0.01. Data are representative of three independent experiments in (D) and (F), and pooled from three experiments in (B), (C), (E), and (G). Horizontal bars indicate the means in (B), (C), and (E).

To further assess the contribution of ILCs to arthritis development, we x-irradiated Thy1.1^+^ *Rag2*^−/−^ mice, reconstituted them with BM cells from Thy1.1^+^ *Rag2*^−/−^ mice and Thy1.2^+^ *Csf2*^−/−^ SKG mice at a 1:1 ratio, and treated the mice 6 weeks later with a single injection of 20 mg mannan and subsequently with 500 μg anti-Thy1.1 mAb once a week. Anti-Thy-1.1 treatment selectively depleted synovial Thy1.1^+^ GM-CSF-producing ILCs, while control mAb treatment allowed similar expansion of synovial Thy1.1^+^ GM-CSF-producing ILCs and Thy1.2^+^ GM-CSF-nonproducing ILCs ([Figure 5](#fig5){ref-type="fig"}F). This selective depletion of synovial GM-CSF-producing ILCs significantly reduced the severity of arthritis ([Figure 5](#fig5){ref-type="fig"}G).

These results collectively indicate that GM-CSF from both ILCs and radio-resistant stromal cells synergistically contributes to the development of severe autoimmune arthritis in SKG mice.

IL-2, IL-33, and TLR-9 Ligands Control GM-CSF Production by Synovial ILCs {#sec2.6}
-------------------------------------------------------------------------

Given the finding that IL-2, IL-7, and IL-33 control the effector function of ILC2s in inflamed tissues ([@bib31]), we assessed their contribution to GM-CSF production by ILCs. Among various tissue homogenates prepared from normal mice, joint tissues substantially expressed IL-33, which significantly increased in arthritic joints at both the mRNA and protein levels compared with unaffected joints ([Figures 6](#fig6){ref-type="fig"}A and 6B). This was consistent with the finding by others that IL-33 was constitutively expressed in the nucleus of some immune cells and stromal cells in inflamed joints ([@bib17], [@bib30]). We next sorted synovial ILCs and treated them *in vitro* with IL-2, IL-7, or IL-33 alone or in combination to assess the effects of these cytokines on GM-CSF production by ILCs. Intriguingly, IL-2, but not IL-7, in combination with IL-33 synergistically upregulated GM-CSF production from synovial ILCs, while the IL-2 and IL-33 combination or the IL-7 and IL-33 combination significantly increased the ILC2 signature cytokines IL-13 and IL-5 ([Figure 6](#fig6){ref-type="fig"}C). We also examined possible expression of TLRs by synovial ILCs, as reported with human ILCs in the tonsil and the intestine ([@bib13], [@bib33]). Quantitative RT-PCR analysis revealed that synovial ILCs highly expressed *Tlr2*, *Tlr3*, *Tlr4*, and *Tlr9* relative to naive Th cells as a negative control ([Figure 6](#fig6){ref-type="fig"}D). Moreover, *in vitro* stimulation of synovial ILCs with TLR ligands alone or in combination with IL-33 showed that stimulation with each TLR ligand alone failed to induce any GM-CSF production, but CpG DNA, a TLR-9 ligand, in combination with IL-33 significantly increased GM-CSF production more than IL-33 alone ([Figure 6](#fig6){ref-type="fig"}E). Taken together, IL-33, IL-2, and TLR-9 ligands, especially their combination, in inflamed synovia are able to augment GM-CSF production by synovial ILCs.Figure 6Control of GM-CSF Production in Synovial ILCs by IL-2, IL-33, and TLR-9 Ligands(A) Quantity of the active form IL-33 assessed by ELISA (Biolegend, Mouse IL-33 ELISA kit) in indicated tissue homogenates.(B) Quantitative RT-PCR for *Il33* expression and ELISA for IL-33 protein in arthritic or control joints. Symbols represent individual mice.(C) Production of cytokines by synovial ILCs. Synovial ILCs (5 × 10^3^) from arthritic joints were purified and cultured for 24 hr with rhIL-2 (20 U/mL), rmIL-7 (20 ng/mL), and rmIL-33 (20 ng/mL) alone or in combination. The concentration of IL-5, IL-13, and GM-CSF in the supernatant was measured (n = 3).(D) Quantitative RT-PCR analysis of the expression of indicated TLR genes in naive CD4^+^ T cells and synovial ILCs as shown in [Figure 4](#fig4){ref-type="fig"}M (n = 3).(E) GM-CSF production by synovial ILCs. Synovial ILCs (5 × 10^3^) were cultured for 24 hr with poly(I:C) (1 μg/mL), LPS (1 μg/mL), and CpG DNA (1 μM) alone or in combination with rmIL-33 (20 ng/mL). The concentration of GM-CSF in the supernatant was measured (n = 3).^∗∗^p \< 0.01. Data are representative of at least two independent experiments. Horizontal bars indicate the means in (A) and (B). Vertical bars indicate SD in (C)--(E).

GM-CSF-Producing ILCs in Synovial Fluid of RA Patients {#sec2.7}
------------------------------------------------------

With the key role of ILC-derived GM-CSF for the development of arthritis in SKG mice, we next evaluated the proportion and cytokine profile of ILCs in peripheral blood and synovial fluid (SF) obtained from RA or osteoarthritis (OA) patients. All the RA patients examined fulfilled the RA classification criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) 2010. The patients were 67.9 ± 8.9 (mean ± SD) years old, with disease duration of 25.4 ± 11.8 years. Anti-CCP antibody and rheumatoid factor were positive in all the patients. Disease activity scores in 28 joints using erythrocyte sedimentation rate (DAS28-ESR) were 3.0 ± 0.5. Among 10 patients, 7 were treated with methotrexate, 6 with biological or targeted synthetic disease-modifying anti-rheumatic drugs (tocilizumab; 2, etanercept; 1, golimumab; 1, abatacept; 1, tofacitinib; 1), and 9 with glucocorticoids (4.6 ± 2.1 mg/day prednisolone). The patients with OA were 77.7 ± 4.5 (mean ± SD) years old and fulfilled the grade 4 of Kellgren-Lawrence system for classification of OA. None of the OA patients were treated with immunosuppressive drugs or glucocorticoids. ILCs comprised a sizable fraction (∼3%) of CD45^+^ hematopoietic cellular elements in SF from RA patients and were significantly increased when compared with ILCs in the peripheral blood of RA patients or those in SF from OA patients ([Figures 7](#fig7){ref-type="fig"}A, [S2](#mmc1){ref-type="supplementary-material"}B, and S2C for gating strategies). Notably, the total numbers of SF ILCs from RA patients were markedly increased by ∼100-fold compared with those from OA patients ([Figure 7](#fig7){ref-type="fig"}B). The ratio of ILCs expressing GM-CSF, IFN-γ, or IL-17 significantly increased, in RA SF compared with RA peripheral blood, with a significant reduction of the ratio of IL-13-expressing SF ILCs, although the latter appeared to increase in absolute number in RF SF compared with OA SF ([Figure 7](#fig7){ref-type="fig"}C). The majority of GM-CSF-producing cells in SF was CD3^+^ T cells (∼80%), followed by CD11b^+^ myeloid cells (∼15%) and ILCs (∼5%) ([Figures 7](#fig7){ref-type="fig"}D and 7E). Thus, GM-CSF-producing synovial ILCs greatly expanded in inflamed joints of RA patients and shared a similar inflammatory signature between mice and humans. The difference in the cytokine expression profile, especially in IFN-γ and IL-13 expression, and in the cellular frequencies between human and mouse synovial ILCs could be attributed, at least in part, to the methods of sample collections (synovial tissues in mice versus SF in humans) as well as medications in the patients, different disease courses and stages, variable treatment periods, heterogeneity of disease types, and heterogenous genetic backgrounds of humans.Figure 7GM-CSF-Producing ILCs in Synovial Fluid of RA Patients(A) The presence of ILCs (defined as CD45^+^CD3^−^CD4^−^CD8^−^CD11b^−^CD11c^−^CD19^−^CD56^−^) from peripheral blood (PB) or synovial fluid (SF) of a patient with RA or OA (left). The percentages of ILCs in PB and SF from individual RA (n = 13) or OA (n = 6) patients. The lines indicate the sample pairs of the same patients (right).(B) Total numbers of ILCs in 1 mL of SF from OA and RA patients (n = 6). Vertical bars indicate SD.(C) Flow cytometry analysis of IFN-γ, IL-13, IL-17, and GM-CSF expression by ILCs (gated as in A) in PB or SF of a RA patient (top). The percentages of cytokine-producing ILCs from individual RA patients (n = 11) (bottom).(D) Gating strategies for GM-CSF^+^CD45^+^ lineage markers-negative (ILCs), GM-CSF^+^CD45^+^CD3^−^CD11b^+^ (myeloid cells), and GM-CSF^+^CD45^+^CD11b^−^CD3^+^ cells (T cells).(E) Proportion of GM-CSF-producing cells (n = 3). Vertical bars indicate SD. Symbols represent individual samples. Horizontal bars indicate the means.^∗^p \< 0.05, ^∗∗^p \< 0.01.

Discussion {#sec3}
==========

The main finding in this report is that arthritogenic Th17 cells are able to stimulate via IL-17 radio-resistant stromal cells including FLSs to secrete GM-CSF, and also synovial-resident ILCs to expand and produce GM-CSF in inflamed joints. Abrogation of GM-CSF production by either the stromal cells or ILCs is able to prevent Th17 cell-mediated arthritis, while GM-CSF from arthritogenic Th cells is contributory to but not mandatory for arthritis development, at variance with a crucial role of Th17 cell-derived GM-CSF in mouse EAE ([@bib11], [@bib16]). The present results do not exclude possible contribution of GM-CSF-producing radio-resistant lymphocytes and non-lymphoid stromal cells other than ILCs and FLSs, inside or outside the joint, to disease manifestation in SKG mice and BM chimeras. Nevertheless, these results strongly support the notion that GM-CSF-producing radio-resistant stromal cells and synovial ILCs are critical components of a key inflammatory cellular cascade for the development of autoimmune arthritis.

It has been well substantiated in RA that FLSs in the synovial intimal lining are key effector cells producing large amounts of inflammatory mediators and proteolytic enzymes, such as matrix metalloproteinases (MMPs) and cathepsins, which degrade cartilage and bone ([@bib4]). IL-1 and TNF-α synergistically induce GM-CSF in FLSs ([@bib2]). Stimulation with IL-17 in combination with IL-1 and TNF-α enhances the production of IL-6 and MMPs by FLSs ([@bib9]). Here, we have shown that *in vitro* stimulation of SKG FLSs with IL-17 increases FLS-derived production of neutrophil-recruiting chemokines and GM-CSF, as previously reported with RA synoviocytes ([@bib18], [@bib47]) and that loss of GM-CSF production by radio-resistant stromal cells including FLSs prevents arthritis development. Since the induction of arthritis is dependent on IL-17 from autoimmune Th cells in our model ([@bib22]), it is likely that Th17 cells stimulated the stromal cells via IL-17 to produce GM-CSF. This can be a key early event to initiate micro-inflammation, which in turn mediates a downstream inflammatory cascade, leading to overt joint inflammation accompanying the infiltration and expansion of Th17 cells, ILCs, neutrophils, and inflammatory monocytes.

GM-CSF-producing synovial-resident ILCs expand in inflamed joints and augment autoimmune arthritis. Among group 1, 2, and 3 ILCs, which are classified by their expression of signature cytokines and master transcription factors ([@bib7], [@bib15], [@bib45]), ILC2s mediate type 2 immunity including allergic reactions and host defense against parasite infections ([@bib36], [@bib38], [@bib41], [@bib49]). We have shown here that CD25^+^IL-33Ra^+^GATA-3^+^ ILC2s actively secreting GM-CSF are a major ILC subset expanding in inflamed joints and that depletion of total ILCs by anti-Thy1 antibody or loss of GM-CSF production in ILCs, without affecting the expansion of GM-CSF-nonproducing synovial ILCs, is able to effectively prevent autoimmune arthritis. Notably, these GM-CSF-producing synovial ILCs are physiologically present in healthy joints of any mouse strain. In addition, the presence of synovial ILCs in healthy joints and the paucity of ILCs in lymphoid organs or blood ([@bib3], [@bib26]) indicate that ILC's precursors with the capacity to give rise to ILC1s, ILC2s, and ILC3s preferentially migrate from the BM, their primary site of generation, and differentiate into GM-CSF-producing ILCs in the synovia. While bidirectional plasticity between ILC1s and ILC3s was recently observed in the intestinal lamina propria ([@bib6]), synovial ILC2s did not appear to originate from ILC3s, which is the major GM-CSF producer in the intestine of mice and humans ([@bib19], [@bib37]). These results collectively suggest that GM-CSF may not be an ILC subset-specific cytokine but can be produced by ILC1s, ILC2s, and ILC3s in an environment-dependent manner, as a recent comprehensive transcriptome analysis of ILC subsets showed *Csf2* as one of shared transcriptional signatures ([@bib40]). In addition, Bhlhe40, which transcriptionally increases the expression of proinflammatory cytokines including GM-CSF in Th1 and Th17 cells ([@bib32], [@bib34]), may be another shared molecule driving *Csf2* among ILC subsets and may also induce the pathogenicity of GM-CSF-producing synovial ILCs in autoimmune arthritis. It remains to be determined how such synovial ILCs are maintained as a cellular constituent of the normal joint and what physiological roles GM-CSF-producing synovial ILCs play in healthy joints.

GM-CSF production by ILCs is stimulated by the alarmin IL-33 and further enhanced by IL-2 and TLR-9 ligands. Synovial ILCs highly expressed CD25 and IL-33Ra, enabling their ligands IL-2 and IL-33, which are abundantly present in inflamed joints, to control GM-CSF production. In addition to well-characterized IL-2- and IL-33-dependent ILC2 control, we have shown in the current study that synovial ILCs expressed functional cytoplasmic TLR9, which may sense mitochondrial DNA (containing unmethylated CpG repeats, a bacterial molecular motif) possibly released as an endogenous damage-associated molecular pattern (DAMPs) ([@bib52]). In addition, extracellular mitochondrial DNA, which could experimentally induce arthritis in animals, was reported to be detectable in synovial fluid of RA patients ([@bib12]). Taken together, synovial ILCs expressing CD25, IL-33Ra, and cytoplasmic TLR9 may sense IL-2, IL-33, and self DNA, which are produced by pathogenic Th cells or released from necrotic joint inflammatory cells, leading to their production of GM-CSF ([@bib50]).

GM-CSF is abundant in RA synovium and upregulated by IL-1 and TNF-α and by IL-17 ([@bib2], [@bib47]). Anti-GM-CSFRα or anti-GM-CSF showed significant clinical efficacy in RA patients without major adverse effects such as pulmonary alveolar proteinosis, which is caused by autoantibodies against GM-CSF ([@bib5], [@bib8]). As GM-CSF-producing ILCs, stromal cells, and T cells sense different inflammatory cues such as DAMPs, inflammatory cytokines, and recognition of self-antigens, respectively, in joint inflammation, the importance of each source of GM-CSF may depend on the phase of joint inflammation. For example, GM-CSF from ILCs appears to play a key role in the initiation of autoimmune arthritis, while T cell-derived GM-CSF may contribute to chronic progression of the disease. For better control of local tissue inflammation in RA and other immunological diseases, it is required to further elucidate how GM-CSF production is controlled in T cells, FLSs, and ILCs at various inflammation stages, and how these cell populations interact spatio-temporarily via GM-CSF.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-mouse CCR6 (29-2L17)-PEBiolegendCat\#129803; RRID: [AB_1279139](nif-antibody:AB_1279139){#intref0010}Anti-mouse CD3e (145-2C11)-BiotinBD BiosciencesCat\#553060; RRID: [AB_394593](nif-antibody:AB_394593){#intref0015}Anti-mouse CD4 (RM4-4)-BiotinBiolegendCat\#116010; RRID: [AB_2561504](nif-antibody:AB_2561504){#intref0020}Anti-mouse CD8 (53-6.7)-BiotinBiolegendCat\#100704; RRID: [AB_312743](nif-antibody:AB_312743){#intref0025}Anti-mouse/human CD11b (M1/70)-BiotinBiolegendCat\#101203; RRID: [AB_312786](nif-antibody:AB_312786){#intref0030}Anti-mouse CD11c (HL3)-BiotinBD BiosciencesCat\#553800; RRID: [AB_395059](nif-antibody:AB_395059){#intref0035}Anti-mouse CD16/32 (2.4G2)BD BiosciencesCat\#553142; RRID: [AB_394657](nif-antibody:AB_394657){#intref0040}Anti-mouse CD19 (1D3)-BiotinBD BiosciencesCat\#553784; RRID: [AB_395048](nif-antibody:AB_395048){#intref0045}Anti-mouse CD25 (PC61)-PEBD BiosciencesCat\#553866; RRID: [AB_395101](nif-antibody:AB_395101){#intref0050}Anti-mouse CD44 (IM7)-PEBD BiosciencesCat\#553134; RRID: [AB_39464](nif-antibody:AB_39464){#intref0055}Anti-mouse CD45.2 (104)-APCBiolegendCat\#109814; RRID: [AB_389211](nif-antibody:AB_389211){#intref0060}Anti-mouse c-Kit (2B8)-PEBiolegendCat\#105807; RRID: [AB_313216](nif-antibody:AB_313216){#intref0065}Anti-mouse Foxp3 (FJK-16S)-APCeBioscienceCat\#17-5773-82; RRID: [AB_469457](nif-antibody:AB_469457){#intref0070}Anti-mouse Gata-3 (TWAI)-PEeBioscienceCat\#12-9966-42; RRID: [AB_1963600](nif-antibody:AB_1963600){#intref0075}Anti-mouse GM-CSF (MP1-22E9)-PEBD BiosciencesCat\#554406; RRID: [AB_395371](nif-antibody:AB_395371){#intref0080}Anti-mouse GM-CSFRa (698423)-APCR&D systemsCat\#FAB6130A; RRID: [AB_10973836](nif-antibody:AB_10973836){#intref0085}Anti-mouse IFN-γ (XMG1.2)-eF450eBioscienceCat\#48-7311-82; RRID: [AB_1834366](nif-antibody:AB_1834366){#intref0090}Anti-mouse IL-13 (eBio13A)-eF450eBioscienceCat\#48-7133-82; RRID: [AB_11219690](nif-antibody:AB_11219690){#intref0095}Anti-mouse IL-17 (TC11-18H10.1)-BV421BiolegendCat\#506926; RRID: [AB_2632611](nif-antibody:AB_2632611){#intref0100}Anti-mouse IL-7Ra (SB/199)-PEBD BiosciencesCat\#552543; RRID: [AB_394417](nif-antibody:AB_394417){#intref0105}Anti-mouse/human Ki-67 (MKI67)-PEBD BiosciencesCat\#556027; RRID: [AB_2266296](nif-antibody:AB_2266296){#intref0110}Anti-mouse IL-33Ra (D1H9)-PEBiolegendCat\#145304; RRID: [AB_2561915](nif-antibody:AB_2561915){#intref0115}Anti-mouse Ly-6C (AL-21)-FITCBD BiosciencesCat\#553104; RRID: [AB_394628](nif-antibody:AB_394628){#intref0120}Anti-mouse Ly-6G (1A8)-PEBiolegendCat\#127608; RRID: [AB_1186099](nif-antibody:AB_1186099){#intref0125}Anti-mouse MHC2 (M5/114.15.2)-BV421BiolegendCat\#107631; RRID: [AB_10900075](nif-antibody:AB_10900075){#intref0130}Anti-mouse Pan-NK (DX-5)-BiotinBiolegendCat\#108904; RRID: [AB_313411](nif-antibody:AB_313411){#intref0135}Anti-mouse Podoplanin (8.1.1)-APCBiolegendCat\#127410; RRID: [AB_10613649](nif-antibody:AB_10613649){#intref0140}Anti-mouse Rorγt (AFKJS-9)-PEeBioscienceCat\#12-6988-82; RRID: [AB_1834470](nif-antibody:AB_1834470){#intref0145}Anti-mouse TCR-β (H57-597)-APCBiolegendCat\#109212; RRID: [AB_313435](nif-antibody:AB_313435){#intref0150}Anti-mouse T-bet (4B10)-BV421BiolegendCat\#644815; RRID: [AB_10896427](nif-antibody:AB_10896427){#intref0155}Anti-mouse Thy1.1 (OX-7)-FITCBD BiosciencesCat\#554897; RRID: [AB_395588](nif-antibody:AB_395588){#intref0160}Anti-mouse Thy1.2 (53-2.1)-FITCBiolegendCat\#140304; RRID: [AB_10642812](nif-antibody:AB_10642812){#intref0165}Anti-mouse Thy1.2 (53-2.1)-BV421BiolegendCat\#140327; RRID: [AB_2686992](nif-antibody:AB_2686992){#intref0170}Anti-human CD3 (UCHT1)-BiotinBiolegendCat\#300404; RRID: [AB_314058](nif-antibody:AB_314058){#intref0175}Anti-human CD3 (UCHT1)-Alexa488BiolegendCat\#300454; RRID: [AB_2564149](nif-antibody:AB_2564149){#intref0180}Anti-human CD4 (OKT4)-BiotinBiolegendCat\#317406; RRID: [AB_571949](nif-antibody:AB_571949){#intref0185}Anti-human CD8 (SK1)-BiotinBiolegendCat\#344720; RRID: [AB_2075392](nif-antibody:AB_2075392){#intref0190}Anti-mouse/human CD11b (M1/70)-PEeBioscienceCat\#12-0112-81; RRID: [AB_465549](nif-antibody:AB_465549){#intref0195}Anti-human CD11c (3.9)-BiotinBiolegendCat\#301612; RRID: [AB_493021](nif-antibody:AB_493021){#intref0200}Anti-human CD19 (HIB19)-BiotinBiolegendCat\#302204; RRID: [AB_314234](nif-antibody:AB_314234){#intref0205}Anti-human CD45 (HI30)-BV421BiolegendCat\#304032; RRID: [AB_2561357](nif-antibody:AB_2561357){#intref0210}Anti-human CD56 (HCD56)-BiotinBiolegendCat\#318320; RRID: [AB_893390](nif-antibody:AB_893390){#intref0215}Anti-human GM-CSF (BVD2-21C11)-APCBiolegendCat\#502310; RRID: [AB_11150231](nif-antibody:AB_11150231){#intref0220}Anti-human IFN-γ (4S.B3)-Alexa488BiolegendCat\#502515; RRID: [AB_493029](nif-antibody:AB_493029){#intref0225}Anti-human IL-13 (JES10-5A2)-PEBiolegendCat\#501903; RRID: [AB_315198](nif-antibody:AB_315198){#intref0230}Anti-human IL-17 (BL168)-Alexa488BiolegendCat\#512308; RRID: [AB_961386](nif-antibody:AB_961386){#intref0235}PECy7-StreptavidinBD BiosciencesCat\#557598; RRID: [AB_10049577](nif-antibody:AB_10049577){#intref0240}Anti-mouse Thy1.1 (19E12)Bio X CellCat\#BE0214; RRID: [AB_2687700](nif-antibody:AB_2687700){#intref0245}Anti-mouse Thy1.2 (30H12)Bio X CellCat\#BE0066; RRID: [AB_1107682](nif-antibody:AB_1107682){#intref0250}Isotype control Rat IgG2b (LTF-2)Bio X CellCat\#BE0090; RRID: [AB_1107780](nif-antibody:AB_1107780){#intref0255}**Chemicals, Peptides, and Recombinant Proteins**Mannan from Saccharomyces cerevisiaeSigma-AldrichCat\#M7504Phorbol 12-myristate 13-acetateSigma-AldrichCat\#P1585IonomycinSigma-AldrichCat\#I0634Brefeldin AMerckCat\#203729Liberase TM Research GradeRocheCat\#0540111901TRIzolInvitrogenCat\#15596026IMDMSigma-AldrichCat\#I3390-500MLDMEMNacalai TesqueCat\#08459-35Penicillin-streptomycin solutionNacalai TesqueCat\#26252-9437% Formaldehyde solutionSigma-AldrichCat\#F8775-25MLNP-40Nacalai TesqueCat\#23640-94rhIL-2Shionogi Co.6399411D1022rmIL-7R&D systemsCat\#407-ML-005rmIL-33R&D systemsCat\#3626-ML-010Poly(I:C)InvivoGenCat\#tlrl-picwLPSInvivoGenCat\#tlrl-3pelpsCpGDNAInvivoGenCat\# tlrl-1585FBSGIBCOCat\#10437-028HBSSNacalai TesqueCat\#17460-015Sodium AzideNacalai TesqueCat\#31208-82Ficoll-Paque PLUSGE HealthcareCat\#17-1440-032-MercaptoethanolGIBCOCat\#21985-023Sodium pyruvateGIBCOCat\#11360-070GlutaMAXGIBCOCat\#35050-61MEM NEAAGIBCOCat\#11140-05070 μm filter meshBD BiosciencesCat\#352350**Critical Commercial Assays**Foxp3 Staining Buffer SeteBioscienceCat\#00-5523-00Mouse IL-33 ELISA KitBiolegendCat\#436407Arthrogen-CIA 5-Clone Cocktail KitChondrexCat\#53040BD Cytometric Bead Array (IL-5)BD BiosciencesCat\#558302BD Cytometric Bead Array (IL-13)BD BiosciencesCat\#558349BD Cytometric Bead Array (GM-CSF)BD BiosciencesCat\#558347CD4 MicroBeadsMiltenyi BiotecCat\#130-049-201LS ColumnMiltenyi BiotecCat\#130-042-401qPCR Master MixTOYOBOCat\#QPS-101SuperScript VILO Master MixInvitrogenCat\#11756050TaqMan Gene Expression (*Bhlhe40*)ABIMm00478593_m1TaqMan Gene Expression (*Ccl20*)ABIMm01268754_m1TaqMan Gene Expression (*Csf2*)ABIMm00438328_m1TaqMan Gene Expression (*Cxcl1*)ABIMm04207460_m1TaqMan Gene Expression (*Cxcl5*)ABIMm00436451_g1TaqMan Gene Expression (*Hprt*)ABIMm01545399_m1TaqMan Gene Expression (*Il1b*)ABIMm00434228_m1TaqMan Gene Expression (*Il6*)ABIMm00446190_m1TaqMan Gene Expression (*Il33*)ABIMm00505403_m1TaqMan Gene Expression (*Lif*)ABIMm00434762_g1TaqMan Gene Expression (*Nfkbiz*)ABIMm00600522_m1TaqMan Gene Expression (*Tlr1*)ABIMm00446095_m1TaqMan Gene Expression (*Tlr2*)ABIMm00442346_m1TaqMan Gene Expression (*Tlr3*)ABIMm01207404_m1TaqMan Gene Expression (*Tlr4*)ABIMm00445273_m1TaqMan Gene Expression (*Tlr5*)ABIMm00546288_s1TaqMan Gene Expression (*Tlr6*)ABIMm02529782_s1TaqMan Gene Expression (*Tlr7*)ABIMm00446590_m1TaqMan Gene Expression (*Tlr9*)ABIMm00446193_m1TaqMan Gene Expression (*Tnf*)ABIMm00443260_g1TaqMan Gene Expression (*Zc3h12a*)ABIMm00462533_m1**Software and Algorithms**FlowJoTree Star, Inc.<https://www.flowjo.com>GraphPad PRISMGraphPad Software, Inc.<https://www.graphpad.com/>BD Cytometric Bead Array FCAP Array SoftwareBD BiosciencesCat\# 652099**Other**BD FACS Canto IIBD Biosciences<http://www.bdbiosciences.com/us/instruments/research/cell-analyzers/bd-facscanto-ii/m/744810/features>BD FACS Aria SORPBD BiosciencesN/ARoche LightCycler 480Roche<https://lifescience.roche.com/global_en/products/lightcycler14301-480-instrument-ii.html>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Requests for data or reagents should be directed and will be fulfilled by the Lead Contact, Shimon Sakaguchi (<shimon@ifrec.osaka-u.ac.jp>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

SKG ([@bib42]), *Il17a*^−/−^ SKG ([@bib22]), *Rag2*^−/−^ ([@bib43]), *Csf2*^−/−^ ([@bib44]), Thy1.1 congenic ([@bib43]) mice were used. C57/BL6J mice were purchased from CLEA Japan. *Il17a*^*Cre*^, R26R^FP635^, and R26R^eYFP^ mice were backcrossed to SKG for more than eight generations ([@bib24]). *Csf2*^−/−^ SKG, *Csf2*^−/−^ *Rag2*^−/−^, *Il17a*^*Cre*^ R26R^FP635^, *Il17a*^*Cre*^ R26R^eYFP^, Thy1.1 congenic SKG or *Rag2*^−/−^ mice were generated by crossing the strains described above. All the genetically modified mouse strains used in this study were on the BALB/c background and kept under specific pathogen-free conditions. Both male and female mice at 8-12 weeks of age were used for all the experiments. All animal experiments were approved by the Animal Ethical Committee of Immunology Frontier Research Center, Osaka University and Institute for Frontier Life and Medical Sciences, Kyoto University, and performed in accordance with institutional guidelines.

### Induction of autoimmune arthritis {#sec4.3.2}

Arthritis was induced by either a single injection of 20 mg mannan (Sigma-Aldrich) intraperitoneally ([@bib20]), or adoptive transfer of CD4^+^ T cells intravenously (i.v.) ([@bib22]). CD4^+^ T cells were sorted from the spleen and peripheral LNs of SKG mice using MACS CD4 microbeads and LS column (Miltenyi Biotec) according to the manufacturer's instruction. For depletion of ILCs, purified anti-Thy1.1 (19E12; Bio X cell), anti-Thy1.2 (30H12; Bio X Cell) or isotype control Rat IgG2b (LTF-2; Bio X Cell) antibody was i.v. injected. Joint swelling was scored as follows: 0, no joint swelling; 0.1, swelling of one finger joint; 0.5, mild swelling of wrist or ankle; 1.0, severe swelling of wrist or ankle. Scores for all fingers of forepaws and hindpaws, wrists and ankles were totaled for each mouse.

### Patient information {#sec4.3.3}

Detailed information about RA or OA patients is described in the section of Results. Synovial fluid samples from RA or OA patients were obtained at the time of arthrocentesis or surgical operation and cellular fractions were analyzed by flow cytometry. Samples from peripheral blood were taken from the same patients at different time points. Peripheral blood mononuclear cells were separated using Ficoll-Paque PLUS (GE Healthcare). This study has been approved by the Ethical Committee of Kyoto University. Written informed consent was obtained from all the participants.

Method Details {#sec4.4}
--------------

### Flow cytometry {#sec4.4.1}

The following monoclonal antibodies were used for flow cytometry analysis (BD FACSCantoII) and cell sorting (BD FACSAria SORP): anti-mouse CCR6 (29-2L17, Biolegend), CD3e (145-2C11, BD Biosciences), CD4 (RM4-4, Biolegend), CD8 (53-6.7, Biolegend), CD11b (M1/70, Biolegend), CD11c (HL3, BD Biosciences), CD16/32 (2.4G2, BD Biosciences), CD19 (1D3, BD Biosciences), CD25 (PC61, BD Biosciences), CD44 (IM7, BD Biosciences), CD45.2 (104, Biolegend), c-Kit (2B8, Biolegend), Foxp3 (FJK-16S, eBioscience), Gata-3 (TWAI, eBioscience), GM-CSF (MP1-22E9, BD Biosciences), GM-CSFRa (698423, R&D systems), IFN-γ (XMG1.2, eBioscience), IL-13 (eBio13A, eBioscience), IL-17 (TC11-18H10.1, Biolegend), IL-7Ra (SB/199, BD Biosciences), Ki-67 (MKI67, BD Biosciences), IL-33Ra (D1H9, Biolegend), Ly-6C (AL-21, BD Biosciences), Ly-6G (1A8, Biologend), MHC2 (M5/114.15.2, Biolegend), Pan-NK (DX-5, eBioscience), Podoplanin (8.1.1, Biolegend), Rorγt (AFKJS-9, eBioscience), TCR-β (H57-597, Biolegend), T-bet (4B10, Biolegend), Thy1.1 (OX-7, BD Biosciences), Thy1.2 (53-2.1, Biolegend), anti-human CD3 (UCHT1, Biolegend), CD4 (OKT4, Biolegend), CD8 (SK1, Biolegend), CD11b (M1/70, eBioscience), CD11c (3.9, Biolegend), CD19 (HIB19, Biolegend), CD45 (HI30, Biolegend), CD56 (HCD56, Biolegend), GM-CSF (BVD2-21C11, Biolegend), IFN-γ (4S.B3, Biolegend), IL-13 (JES10-5A2, Biolegend), IL-17 (BL168, Biolegend), PECy7-Streptavidin (BD Biosciences). For intracellular staining for transcription factors, cells were stained using Foxp3 staining buffer set (eBioscience) according to the manufacturer's instruction. For intracellular staining for cytokines, cells were restimulated in IMDM buffer (Sigma-Aldrich) supplemented with 5% FBS (GIBCO), penicillin-streptomycin (Nacalai Tesque), 2-Mercaptoethanol (GIBCO), GlutaMAX (GIBCO), sodium pyruvate (GIBCO), and MEM NEAA (GIBCO) for 4 h with phorbol 12-myristate 13-acetate (50 ng/ml; Sigma-Aldrich) and ionomycin (500 ng/ml; Sigma-Aldrich) in the presence of brefeldin A (1 μg/ml; Merck), fixed with 3.7% formaldehyde (Sigma-Aldrich), permeabilized with 0.1% NP-40 (Nacalai Tesque), and stained with FACS buffer consisting of HBSS (Nacalai Tesque) supplemented with 2% FBS (GIBCO) and 0.1% sodium azide (Nacalai Tesque). All the FACS data were analyzed on FlowJo software.

### Preparation of FLS from inflamed joints {#sec4.4.2}

Inflammatory synovial cells were prepared by cutting the synovial tissues from arthritic joints into small pieces, followed by enzymatic digestion for 30 min at 37°C in plain IMDM buffer (Sigma-Aldrich) with Liberase TM (0.25 mg/ml; Roche), and then by mashing the digested tissues through 70-μm mesh filter (BD Biosciences). The resultant single cell suspension of synovial tissues was used for flow cytometry or cell sorting experiments. Non-hematopoietic synovial cells adherent to culture dishes were passaged several times without any stimulation in DMEM medium (Nacalai Tesque) supplemented with 20% FBS (GIBCO) and penicillin-streptomycin (Nacalai Tesque) in order to remove synovial immune cells and used as FLS.

### Quantitative RT-PCR {#sec4.4.3}

Total RNA from FLS or inflammatory immune cells isolated from arthritic joints was extracted with TRIzol (Invitrogen) and reverse transcribed with SuperScript VILO (Invitrogen) in accordance with the manufacturer's instructions. The resultant cDNAs served as templates for the amplification of genes of interest and a housekeeping gene by LightCycler 480 (Roche) with qPCR Master Mix (TOYOBO) and ABI TaqMan Gene Expression assays (*Bhlhe40*; Mm00478593_m1, *Ccl20*; Mm01268754_m1, *Csf2*; Mm00438328_m1, *Cxcl1*; Mm04207460_m1, *Cxcl5*; Mm00436451_g1, *Hprt*; Mm01545399_m1, *Il1b*; Mm00434228_m1, *Il6*; Mm00446190_m1, *Il33*; Mm00505403_m1, *Lif*; Mm00434762_g1, *Nfkbiz*; Mm00600522_m1, *Tlr1*; Mm00446095_m1, *Tlr2*; Mm00442346_m1, *Tlr3*; Mm01207404_m1, *Tlr4*; Mm00445273_m1, *Tlr5*; Mm00546288_s1, *Tlr6*; Mm02529782_s1, *Tlr7*; Mm00446590_m1, *Tlr9*; Mm00446193_m1, *Tnf*; Mm00443260_g1, Zc3h12a; Mm00462533_m1). The level of target gene expression was quantified after normalization to *Hprt* expression.

### Culture and cytokine measurement of synovial ILCs {#sec4.4.4}

Synovial ILCs (CD3^-^, CD4^-^, CD8^-^, CD11b^-^, CD11c^-^, CD19^-^, Pan-NK^-^, CD45.2^+^, and Thy1.2^+^) from inflamed joints were purified by flow cytometry and cultured overnight in the presence of rhIL-2 (20 U/ml, Shionogi Co.), rmIL-7 (20 ng/ml, R&D systems), rmIL-33 (20 ng/ml, R&D systems), Poly(I:C) (1 μg/ml, InvivoGen), LPS (1 μg/ml, InvivoGen), and CpG DNA (1 μM, InvivoGen). The concentration of IL-5, IL-13, and GM-CSF in the culture supernatant was measured using BD Cytometric Bead Array (BD Biosciences).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Data are shown as mean ± standard error of mean (SEM) or mean ± standard deviation (SD). Statistical analysis was done with GraphPad PRISM. A two-tailed t test was used for statistical analysis. ANOVA and Bonferroni post-test were used for grouped data analysis. *P* value of \< 0.05 was considered statistically significant. Sample sizes for all shown data can be found in the figure legends.
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